The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Mass Drug Administration

Mass Drug Administration

Mass Drug Administration (MDA) is a public health strategy that involves the large-scale, coordinated distribution of medication to an entire population or subgroup, regardless of individual disease status.
This approach aims to reduce the burden of infectious diseases, such as neglected tropical diseases, by decreasing transmission and prevalence within a community.
MDA programs typically target diseases that can be treated with safe, efficacious, and affordable drugs, and are often implemented in areas with limited access to healthcare.
The succesful implementation of MDA requires careful planning, coordination, and community engagement to ensure high coverage rates and treatmetn adherence.
Evaluating the effectiveness of MDA protocols is crucial for optimizing future interventions and enhancing their impact on population health.

Most cited protocols related to «Mass Drug Administration»

We undertook a cross-sectional population-based study in the Western Province of the Solomon Islands during November 2014. This was undertaken in ten villages within three distinct geographical regions within the Western Province (Vona Vona Lagoon, Roviana Lagoon and Rendova, Fig 1). Dwellings in this region are typically made of local wood. Although variable in size and structure, most comprise one to two sleeping quarters for all house inhabitants.
For logistical reasons data collection was integrated with an existing project investigating clinical and serological markers of yaws [15 ], with selected villages having participating in a mass drug administration for trachoma using azithromycin, a drug that is also active against yaws.
Ethics approval for the study was obtained from the London School of Hygiene and Tropical Medicine (LSHTM Ref 6358) and the National Health Research and Ethics Committee of the Solomon Islands Ministry of Health and Medical Services (HRC14/27). Both of these committee’s approved the research study protocols and methodology.
Following permission from community leaders, a public meeting was arranged for all village members where the study procedures and objectives were explained. Written consent was obtained for all participants. Guardians provided consent for participants aged below 18 years. All community members were eligible for this study, which took place at a pre-arranged public place.
All participants were interviewed and examined by a doctor. Assessments were conducted in the local medical clinic where one existed, or an appropriate community space. The doctor was a paediatric trainee registrar who had received specific training on the diagnosis of scabies and impetigo prior to the study, in addition to 18 months of clinical experience in tropical regions of northern Australia. Clinical history was taken in a combination of English and Solomon Island Pijin. Local nursing staff assisted with translation to local dialects (Roviana and Touo) when required. Demographic information including gender, age, and number of household and bedroom inhabitants was recorded.
Examination of the skin focused on bodily regions most commonly affected by scabies and impetigo. For infants and young children, the whole body was fully examined. For older children and adults, examination of sensitive areas such as the groin, buttocks, breasts and torso was only undertaken if there was adequate privacy. All participants who had scabies clinically on history and/or physical examination were asked whether they had similar lesions in these regions. The clinical diagnosis of scabies was based on features including morphology (burrows, papules, nodules, vesicles) and body distribution of rash; presence of pruritus on history or clinical examination evidence of excoriation; contact history with individuals with a similar rash and itch; and consideration of differential diagnoses [1 (link)]. The distribution of scabies lesions was noted using nine pre-defined body regions. Following other studies in the Pacific, scabies severity was classified by the number of lesion present as mild (≤10 lesions), moderate (11–49 lesions) or severe (≥ 50 lesions or crusted scabies) [3 (link)].
Active impetigo was diagnosed on the basis of discrete papular, pustular or ulcerative lesions with associated erythema, crusting, bullae or frank pus. Inactive impetigo was diagnosed by the presence of discrete, non-confluent healed superficial skin lesions. Severity of active impetigo was classified as very mild (≤ 5 lesions), mild (6–10 lesions), moderate (11–49 lesions) or severe (≥ 50 lesions) [3 (link)]. Participants diagnosed with any condition were counselled regarding the diagnosis and provided with an information sheet and referral letter to the nearest medical clinic for treatment according to standard local protocols [16 ].
Publication 2016
Adult Azithromycin Body Regions Breast Buttocks Child Diagnosis Differential Diagnosis Erythema Ethics Committees Exanthema Gender Groin Households Human Body Impetigo Infant Legal Guardians Mass Drug Administration Nursing Staff Pharmaceutical Preparations Physical Examination Physicians Pruritus Scabies Skin Torso Trachoma Treatment Protocols Ulcer Yaws
The study was conducted in the context of a national schistosomiasis and soil-transmitted helminths (STH) control programme in Tanzania, which was established in 2003 with support from the Schistosomiasis Control Initiative (SCI) and funded by the Bill and Melinda Gates Foundation. Following WHO guidelines, the programme classifies communities on the basis of prevalence of schistosomiasis in school-age children, according to three strategies: 1) schools where prevalence is <10%, praziquantel is to be made available in local health centres, 2) schools where prevalence is 10 - 50%, mass treatment of all school age-children in the community is conducted and 3) schools where prevalence is >50%, mass treatment of all school age children plus other high-risk groups in the community is conducted. Because of the widespread distribution of STH in Tanzania, albendazole is co-administered with praziquantel.
In the first year of implementation (2005), five regions1 in coastal Tanzania and six regions in northwest Tanzania will be targeted for mass drug administration. Our study was conducted as part of the intervention in northwest Tanzania. For logistical reasons, data collection was limited to a 670 × 530 km area incorporating Kagera, Mwanza, Shinyanga and Tabora regions (see inset, Figure 1), with the aim of making spatial predictions in all six regions (including Mara and Kigoma).
Publication 2006
Albendazole Child Helminths Mass Drug Administration Praziquantel Schistosomiasis
TUMIKIA (Tuangamize Minyoo Kenya Imarisha Afya; Swahili for Eradicate Worms in Kenya for Better Health) was a cluster-randomised controlled trial done in Kwale County from March 18, 2015, to May 17, 2017. We originally planned to do the trial in two contrasting settings, but financial and practical considerations meant we prioritised work in Kwale, which had benefited from previous mass drug administration for lymphatic filariasis. The county is mostly rural and environmentally and socioeconomically diverse. Hookworm is the predominant soil-transmitted helminth species. Annual school-based deworming with albendazole has been implemented since 2012,10 (link) and community-based treatment for lymphatic filariasis using albendazole and diethylcarbamazine citrate since 2002, albeit intermittently and with low coverage.11 (link) Mass treatment is a community-level intervention so we did a cluster-randomised trial; the study objectives pertain to the individual participant level. The unit of randomisation was a community unit, a government health-service delivery structure serving approximately 1000 households. All community units in Kwale county were eligible for enrolment. The rationale and study design have been published previously.12
The protocol was approved by the Kenya Medical Research Institute and National Ethics Review Committee (SSC Number 2826) and the London School of Hygiene & Tropical Medicine Ethics Committee (7177). An independent data safety monitoring board monitored the trial and approved the statistical analysis plan. Community meetings were held to explain the nature and purpose of the trial to community members and parents or legal guardians, and written informed consent was obtained for participation in assessment surveys and verbal consent for treatment. No incentives were offered for participation.
Publication 2019
Albendazole ARID1A protein, human Clinical Trials Data Monitoring Committees Diethylcarbamazine Citrate Ethics Committees Filarial Elephantiases Helminthiasis Helminths Hookworm Infections Households Legal Guardians Mass Drug Administration Obstetric Delivery Parent
Specimens for performance evaluations of the uRDT were collected at two clinical research sites: Nagongera, Uganda, and a Karen village (TOT), Myanmar. In addition, P. falciparum IBSM studies were performed in Queensland, Australia. For the Uganda and Myanmar uRDT studies, the inclusion criteria for asymptomatic individuals were no fever history in the previous 7 days, axillary temperature less than 37.5°C, the absence of other clinical signs of malaria, and no malaria treatment within the previous 60 days.
In Nagongera, Tororo District, Uganda, 100 random households were selected and visited to recruit children 6 months to 11 years old, as well as their primary caregivers, into a surveillance cohort as previously described.28 (link) All participants provided informed consent. As part of the ongoing cohort study, study participants were required to visit a health clinic every 3 months for routine visits, at which time blood was collected by venipuncture and microscopy was performed. For this study, samples were taken during 2 consecutive routine visits from May to October 2015.
In TOT, Myanmar, study teams visited households and recruited both children and adults as part of an ongoing study to assess mass drug administration (MDA) for malaria elimination. All participants provided informed consent. Pregnant women and children less than 6 months of age were excluded.
Publication 2017
Adult Axilla BLOOD Child Fever Households Malaria Mass Drug Administration Microscopy Pregnant Women Venipuncture
A national cross-sectional survey was conducted in 2008 in order to facilitate the planning of mass drug administration for both schistosomiasis and STH. Although it is known that schistosomiasis is prevalent in Sierra Leone, particularly, in the northern and eastern regions, data were not available in terms of detailed distribution and level of risk of the disease throughout the country. It was decided that all 12 districts including cities plus the Western Area (excluding the capital Freetown) were subjected to survey to provide an up-to-date map of geographical distribution and level of risk of schistosomiasis and STH in the country. The sample size was determined according to the WHO guide (50 children per school) [21] , but was increased to 100 per school considering the fewer sites used in this survey and the low prevalence data recorded previously within the country [7] . The survey sites (schools) were selected according to administrative districts (four schools per district) using a two-staged random sampling method to avoid two schools being selected from the same chiefdom to ensure a relatively even geographical coverage throughout the country. Therefore, in each district a list of chiefdoms was used as the sampling frame and four chiefdoms were first randomly selected. Within each selected chiefdom, a list of all primary schools was used as the sampling frame and one primary school was randomly selected. In total, 53 schools were selected for survey throughout the country. In Tonkolili which is ecologically heterogeneous with high altitude in the east and low altitude in the west, relevant chiefdoms were selected to represent the two ecological zones. Within each selected school, systematic sampling of children started from high grade classes and proceeded down through the grades with a view of balancing for sex. Approximately around 100 children aged 5 to 16 years per school (range: 36–134) were examined [22] (link), [23] (link). In a few schools, due to large numbers of children present in the classes selected, up to 134 children were examined, while in one school, only 36 children were examined due to the small size of the school.
Publication 2010
Child Genetic Heterogeneity Mass Drug Administration Only Child Reading Frames Schistosomiasis

Most recents protocols related to «Mass Drug Administration»

Two rounds of surveys were conducted; the first round was done between November and December 2019, reaching 490 community members in ten villages. Details of the sample size selection are provided by Finda et al. [30 (link)]. This survey assessed community members’ awareness, knowledge, and preferences for alternative strategies to supplement current interventions for malaria control. The community members were provided with a list of six alternative strategies for malaria control and elimination including (a) larval source management (LSM), (b) spatial repellents (SR), (c) targeted spraying of mosquito swarms (SMS), (d) mass drug administration with ivermectin (MDA-IVM) to reduce vector densities, (e) release of modified mosquitoes (MM), and (f) housing improvement (HI).
The second round of survey was administered between March and June 2022 to 802 community members in 19 villages. This survey aimed to assess community perceptions, awareness, and available opportunities for housing improvement as a malaria control intervention. The villages in the second survey included the 10 villages in the first survey, but individuals surveyed were not necessarily the same. In both surveys, the households were randomly selected with guidance from household lists from the Ifakara Health and Demographic Surveillance System [31 (link)] and community leaders from the respective villages. Lists of households were identified in each sub-village, and a simple random formula was generated in excel. In case a household on the list no longer existed, the closest neighbour-household was visited and recruited to participate in the study. The surveys were administered to one adult household representative only after they had given written consent to participate. The survey was administered using Kobotoolbox™ software [32 ] on electronic tablets.
Publication 2023
Adult Awareness Cloning Vectors Culicidae Dietary Supplements Households Ivermectin Larva Malaria Mass Drug Administration
The pilot project for this study was approved by the PNG Ministry of Health (Registration Number: 20170330). Three rounds of MDA with the AP program were initiated via the grid-based management model in the Trobriand Islands from March to June 2018. The study profile is shown in Fig. 1. The Trobriand Islands were categorized into two groups in this study based on their geographical location: the main island (Kiriwina) and the outer islands (Vakuta, Kitava, Kaduaga, and Simsimla) (Fig. 2).

Study profile *AP, artemisinin-piperaquine; MDA, mass drug administration.

Geographic information of the Trobriand islands.

Trobriand Islands cover 450 km2 of coral atolls off the East Coast of New Guinea. Kiriwina island, located in the Trobriand Islands center, is the main island home to most of the population. This island is surrounded by the outer islands of Vakuta, Kitava, Kaduaga, and Simsimla (Wikipedia, n.d .). The rainy season in this area lasts from November to March, with the rest of the year being dry. According to a WHO report, the main malaria vectors in PNG are Anopheles punctulatus, Anopheles farauti, and Anopheles koliensis (World Health Organization, n.d.).
Kiriwina Rural is a long and narrow island with an area of 290.5 km2. According to the 2011 census, 36,721 people were living in 7,005 households distributed across 33 villages (National Statistical Office, 2011 ).
Publication 2023
Anopheles artemisinine Cloning Vectors Coral Households Malaria Mass Drug Administration piperaquine Rain

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Households Immunization Programs Mass Drug Administration Medical Devices Voluntary Workers
The CHC programme was launched in September 2018 in Grand’Anse department, which comprises 12 communes and is home to approximately 550,000 people in total. The department is located in the most southwestern point of Haiti, a full day’s drive from Port-au-Prince. Although Jeremie (the department capital) is connected to the national highway, many roads are in poor condition, making local community access a challenge. Towns and hamlets are more densely settled along the road network, with some remote mountain and coastal communities accessible only by foot or motorbike. Hurricane Matthew directly hit Grand’Anse in 2016, destroying tens of thousands of homes and interrupting and ultimately delaying Malaria Zero Consortium activities in the area.
Grand’Anse has the highest malaria burden in Haiti, accounting for roughly 50% of all cases in the country since 2016 (MSPP, unpublished data). Epidemiological data from the department (2016–2021) shows an annual average of 7,352 malaria cases (from 43,366 tests), 6,993 treated patients and 7 deaths reported per year (MSPP, unpublished data). The malaria transmission season generally peaks from November to January, following the primary annual rains from September to December.
Five communes (out of 12) were selected for an initial pilot phase that began in 2018. A total of 23 CHC groups were established, at the sub-commune level, covering an estimated 172,190 people (See Table 1 and Fig. 1). The selection of these five communes took into consideration malaria prevalence, but also road access, since these five communes share a common road west from the capital of Grand’Anse department, the city of Jeremie. Malaria Zero implemented mass drug administration (MDA) in 12 defined operational units (OUs) of Anse d’Hainault, Dame Marie, Les Irois, and Moron communes in the fall of 2018. Indoor Residual Spraying (IRS) was implemented in the same OUs except for one in Moron, where long-lasting insecticidal nets (LLIN) were distributed instead due to technical and logistical feasibility in this remote area. IRS treatment was repeated in 2019 in the same areas that received IRS in 2018. The MDA planned in all five communes for early 2020 were cancelled due to several cases of severe side effects after MDA in a neighboring commune as well as the COVID-19 pandemic. In December 2019, the programme expanded to all other communes of the department; however, this paper focuses exclusively on the data from the initial group of CHCs.

Community Health Councils (CHCs) and total population, by commune

CommuneNumber of CHCsTotal population
Anse d’Hainault640,143
Dame Marie642,731
Chambellan429,179
Les Irois325,777
Moron334,360
Total23172,190

Study location, with 2020 malaria incidence data. The location of the original 23 CHCs included in this study are marked with a triangle, while 31 additional CHCs launched in 2019, and excluded from this study, are represented by a diamond. Note that some locations may have more than one CHC

Publication 2023
COVID 19 D-Ala(2)-Met(5)-enkephalinamide Diamond Foot Hurricanes Insecticides Malaria Mass Drug Administration Patients Rain SLC6A2 protein, human Toxic Epidermal Necrolysis Transmission, Communicable Disease
The Enhancing the A in SAFE (ETAS) study is a community randomized study to evaluate cost and community acceptability of enhanced antibiotic trachoma interventions within an endemic county in South Sudan. A population-based prevalence survey will be conducted whereby 30 communities are selected for trachoma assessment. Following the survey, communities will be randomized 1:1 to receive 1 of 2 enhanced antibiotic interventions (Fig. 1). The remaining communities in the county will receive standard-of-care annual MDA. The primary outcomes of the study are the cost of enhanced MDA compared to standard-of-care annual MDA and the community acceptability of enhanced MDA within study communities. A trachoma impact survey will be conducted approximately 12 months following the original trachoma prevalence survey. The total study duration will be approximately 13 months from the start of the community-level census to the time of the 12 month follow up impact survey. This protocol adheres to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines and refers to version 1.2 of the study protocol as revised 5 May 2021.

ETAS study design summary for communities included in the primary outcome analysis. HH = Household; MDA = Mass Drug Administration

Publication 2023
Antibiotics Households Mass Drug Administration Trachoma

Top products related to «Mass Drug Administration»

Sourced in United States, Germany, China, Brazil, Austria
Kolliphor EL is a non-ionic surfactant commonly used in pharmaceutical and cosmetic applications. It serves as a solubilizer, emulsifier, and stabilizer to enhance the solubility and bioavailability of various active ingredients.
Mectizan is a laboratory-tested product developed by the Merck Group. It is designed to facilitate the analysis and experimentation processes within scientific research settings. The core function of Mectizan is to provide a reliable and consistent tool for researchers and laboratory technicians to carry out their work effectively.
Sourced in United States
MassLynx is a software program developed by Waters Corporation to control and operate mass spectrometry instruments. It provides a user interface for instrument control, data acquisition, and data processing. The core function of MassLynx is to enable the operation and management of mass spectrometry-based analytical workflows.
Sourced in United States, United Kingdom, Ireland, Germany, Japan, China, France
The Acquity UPLC BEH C18 column is a reversed-phase liquid chromatography column designed for ultra-high-performance liquid chromatography (UPLC) applications. The column features a sub-2 μm bridged ethylene hybrid (BEH) particle technology that provides efficient and high-resolution separations.
Sourced in United States, Denmark, United Kingdom
STATA version 11 is a software package for statistical analysis, data management, and graphics. It provides a wide range of statistical tools and functions for researchers, analysts, and professionals in various fields. The core function of STATA version 11 is to perform advanced statistical analysis and modeling on data.
Sourced in United States
Azithromycin is an antibiotic medication developed and manufactured by Pfizer. It is a macrolide class antibiotic used to treat a variety of bacterial infections. The core function of Azithromycin is to inhibit bacterial protein synthesis, thereby preventing bacterial growth and replication.
Sourced in United States
Diclofenac sodium salt is a chemical compound used as a laboratory reagent. It is the sodium salt form of diclofenac, a non-steroidal anti-inflammatory drug (NSAID). This salt is commonly used in research and scientific applications, but its specific function or intended use is not provided in this factual description.
Sourced in Australia, United States
NVivo 12 is a qualitative data analysis software that enables users to organize, analyze, and discover insights from unstructured or qualitative data, such as interviews, focus groups, social media, and web content.
Sourced in United Kingdom, India, Germany, Peru
Albendazole is a laboratory product used for the detection and measurement of certain parasitic worms. It functions as an anthelmintic, which means it is effective against parasitic worms. The core function of Albendazole is to aid in the diagnosis and management of parasitic infections.
Sourced in United States, Germany
The Signa 1.5T is a magnetic resonance imaging (MRI) system developed by GE Healthcare. It operates at a field strength of 1.5 Tesla, providing high-quality imaging capabilities for various clinical applications.

More about "Mass Drug Administration"

Mass Drug Administration (MDA) is a public health strategy that involves the large-scale, coordinated distribution of medications to an entire population or subgroup, regardless of individual disease status.
This approach aims to reduce the burden of infectious diseases, such as neglected tropical diseases, by decreasing transmission and prevalence within a community.
MDA programs typically target conditions that can be treated with safe, effective, and affordable drugs, and are often implemented in areas with limited access to healthcare.
The successful implementation of MDA requires careful planning, coordination, and community engagement to ensure high coverage rates and treatment adherence.
Evaluating the effectiveness of MDA protocols is crucial for optimizing future interventions and enhancing their impact on population health.
MDA is closely related to other terms and concepts, such as Kolliphor EL (a surfactant used in drug formulations), Mectizan (the brand name for ivermectin, a medication commonly used in MDA programs), and the MassLynx program (a software used for mass spectrometry data analysis).
The Acquity UPLC BEH C18 column and STATA version 11 are also relevant tools used in MDA research and evaluation.
Medications commonly used in MDA include Azithromycin (an antibiotic), Diclofenac sodium salt (an anti-inflammatory drug), Albendazole (an antiparasitic drug), and others.
Data analysis software like NVivo 12 may be used to support MDA program assessments and decision-making.
Overall, Mass Drug Administration is a crucial public health strategy that leverages the coordinated distribution of medications to combat infectious diseases and improve population health outcomes, especially in resource-limited settings.